Marinus Pharmaceuticals Inc (NASDAQ: MRNS) closed the day trading at $7.52 down -5.05% from the previous closing price of $7.92. On the day, 623997 shares were traded.
Ratios:
For a better understanding of MRNS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.01 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 6.58 whereas as Long-Term Debt/Eq ratio is at 5.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Oppenheimer on August 11, 2023, Downgraded its rating to Perform and sets its target price to $9 from $14 previously.
On January 20, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $23.
On September 30, 2020, Truist started tracking the stock assigning a Buy rating and target price of $35.Truist initiated its Buy rating on September 30, 2020, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’24 when Shafer Christina sold 2,153 shares for $9.56 per share. The transaction valued at 20,583 led to the insider holds 60,308 shares of the business.
MANNING MARTHA E sold 1,894 shares of MRNS for $18,126 on Feb 20 ’24. The SVP, GEN. COUNSEL & CORP. SEC. now owns 52,966 shares after completing the transaction at $9.57 per share. On Feb 16 ’24, another insider, Braunstein Scott, who serves as the CHAIRMAN AND CEO of the company, sold 11,850 shares for $9.94 each. As a result, the insider received 117,789 and left with 223,512 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 13.26 while its Price-to-Book (P/B) ratio in mrq is 24.48.
Stock Price History:
Over the past 52 weeks, MRNS has reached a high of $11.26, while it has fallen to a 52-week low of $5.57.
Shares Statistics:
A total of 54.58M shares are outstanding, with a floating share count of 50.81M. Insiders hold about 7.01% of the company’s shares, while institutions hold 94.03% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from Moderna, Inc. analysts. The consensus estimate for the next quarter is $18.33, with high estimates of $44.52 and low estimates of $7.52.
